Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease (Q37749813)

22 August 2017

1 reference

title

Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease (English)

1 reference

22 August 2017

main subject

cardiovascular disease

1 reference

John W Eikelboom

2

0 references

author name string

Magdalena Sobieraj-Teague

series ordinal

1

1 reference

22 August 2017

publication date

1 May 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

6

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

289-299

1 reference

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

22 August 2017

cites work

1 reference

A metaregression analysis of the dose-response effect of aspirin on stroke

21 January 2018

1 reference

Inhibition of platelet prostaglandin synthetase by oral aspirin

21 January 2018

1 reference

Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects

21 January 2018

1 reference

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

21 January 2018

1 reference

The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study

21 January 2018

1 reference

Variability in responsiveness to oral antiplatelet therapy

21 January 2018

1 reference

Aspirin and clopidogrel resistance: an emerging clinical entity

21 January 2018

1 reference

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis

21 January 2018

1 reference

Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events--a meta-analysis

21 January 2018

1 reference

Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

21 January 2018

1 reference

Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel.

21 January 2018

1 reference

A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention.

21 January 2018

1 reference

Rapid platelet-function assay: an automated and quantitative cartridge-based method

21 January 2018

1 reference

The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy.

21 January 2018

1 reference

Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention

21 January 2018

1 reference

Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment

21 January 2018

1 reference

Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up

21 January 2018

1 reference

Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platele

21 January 2018

1 reference

Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation

21 January 2018

1 reference

Clinical utility of the PFA-100.

21 January 2018

1 reference

Monitoring of clopidogrel action: comparison of methods

21 January 2018

1 reference

Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyzer-100 system in stroke patients

21 January 2018

1 reference

Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis.

21 January 2018

1 reference

Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients.

21 January 2018

1 reference

The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists

21 January 2018

1 reference

Point-of-care testing shows clinically relevant variation in the degree of inhibition of platelets by standard-dose abciximab therapy during percutaneous coronary intervention

21 January 2018

1 reference

A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation

21 January 2018

1 reference

Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy?

21 January 2018

1 reference

Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation

21 January 2018

1 reference

Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

21 January 2018

1 reference

Testing the effect of GPIIb-IIIa antagonist in patients undergoing carotid stenting: correlation between standard aggregometry, flow cytometry and the cone and plate(let) analyzer (CPA) methods.

21 January 2018

1 reference

21 January 2018

1 reference

Variable platelet response to aspirin and clopidogrel in atherothrombotic disease

21 January 2018

1 reference

Resistance to clopidogrel: a review of the evidence

21 January 2018

1 reference

Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance

21 January 2018

1 reference

Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis

21 January 2018

1 reference

Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment

21 January 2018

1 reference

Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.

21 January 2018

1 reference

The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting

21 January 2018

1 reference

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

21 January 2018

1 reference

A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.

21 January 2018

1 reference

Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Pati

21 January 2018

1 reference

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.

21 January 2018

1 reference

Aspirin resistance: position paper of the Working Group on Aspirin Resistance

21 January 2018

1 reference

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FCA.10.20

1 reference

22 August 2017

1 reference